#FDA panel urges rejection of experimental Alzheimer’s drug
“#FDA panel urges rejection of experimental Alzheimer’s drug” WASHINGTON — Government health advisers sharply criticized a closely watched Alzheimer’s drug on Friday, concluding there wasn’t enough evidence that the experimental drug slowed the brain-destroying disease. The panel of outside experts for the Food and Drug Administration agreed that a pivotal study in patients failed to…